Last updated on November 2019

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Brief description of study

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and V938 shedding in participants with advanced/metastatic or recurrent malignancies who receive V938 in Combination with Pembrolizumab (MK-3475). The primary objective is to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (PRP2D) of V938 administered in combination with pembrolizumab.

Clinical Study Identifier: NCT04135352

Find a site near you

Start Over